Paris (AFP)

The Paris Bourse remained in the green (+ 0.42%) at mid-session Wednesday after a hesitant opening, choosing to be optimistic on Christmas Eve and ignore Donald Trump's threats on the plan of American revival.

The CAC 40 index took 22.89 points to 5,489.75 points around 12:40 (11:40 GMT).

On a European scale, stock market indices were also advancing as a whole, Frankfurt taking 0.53% and Milan 0.44%.

Only the London stock exchange fell by 0.30%, still affected by the discussions around Brexit and the consequences on its economy of a mutation of the Covid-19.

On Christmas Eve, investors preferred to see the glass half full after waking up worried about another exit from US President Donald Trump, who threatened not to sign the $ 900 billion stimulus package adopted the day before by Congress after months of blockage.

"Although this information is a stone in the shoe of investors, there is hope that an agreement will finally be found," said David Madden analyst for CMC Markets UK.

This plan is considered essential to get the world's largest economy back on track, and there is little doubt that it will finally be put in place by the next administration at the latest.

At the end of the year, the few investors still present on the markets were making final arbitrages at the end of a month when the CAC 40 fell slightly but where it lost some 8% in an incredible year.

At the European level, the indices oscillate between a slight increase over twelve months in Frankfurt (+ 1.78%) and a drop of 16% in Madrid or 14.5% in London, passing through a drop of 6.5% in Milan.

Among the good news on Wednesday, activity held up much better in France during the November reconfinement than in the spring, with significantly fewer employees on short-time work and a concentrated impact on the sectors affected by the restrictions, according to a study by the Dares.

Abivax steps up research on Covid-19

French biotech soared (+ 36.80% to 31.60 euros) after announcing Tuesday that it had obtained the status of national research priority for the phase 2b / 3 clinical trial of its drug candidate ABX464, allowing it to '' accelerate its research to treat high-risk patients with Covid-19.

Delivery Hero drops

The meal delivery specialist (-1.18% to 117.70 euros) listed in Germany, sought after in times of uncertainty but abandoned when confidence takes over, fell on the DAX index.

Valneva soon on Wall Street?

The Franco-Austrian vaccine specialist (+ 1.01% to 8.04 euros), who is working on a cure for Covid-19, announced on Tuesday the approval by its shareholders, during an extraordinary general meeting, of 'a resolution allowing an IPO in the United States.

Biotech, headquartered in Nantes, is already listed on the Paris Stock Exchange.

© 2020 AFP